Bill Text: DE HB304 | 2015-2016 | 148th General Assembly | Draft
Bill Title: An Act To Amend Title 18 Of The Delaware Code Relating To Insurance Risk Retention Groups.
Spectrum: Moderate Partisan Bill (Democrat 5-1)
Status: (Passed) 2016-06-28 - Signed by Governor [HB304 Detail]
Download: Delaware-2015-HB304-Draft.html
|
SPONSOR: |
Rep. B. Short & Sen. Cloutier & Sen. Henry & Sen. Hall-Long |
|
Reps. Baumbach, Bentz, Dukes, Mitchell, Paradee, Wilson; Sens. Ennis, Lopez |
|
HOUSE OF REPRESENTATIVES 148th GENERAL ASSEMBLY |
|
HOUSE CONCURRENT RESOLUTION NO. |
|
DIRECTING PREPARATION OF AN ESTIMATE FOR INCLUSION OF ABUSE DETERRENT FORMULATION TECHNOLOGIES FOR OPIOIDS IN STATE EMPLOYEE HEALTH PLAN AND MEDICAID COVERAGE. |
WHEREAS, the majority of drug overdose deaths in Delaware occur from abuse and misuse of opioids and will be examined by the recently established Drug Overdose Fatality Review Commission created by this General Assembly; and
WHEREAS, the State should examine all available measures to control the misuse and abuse of prescription medications with too many Delawareans dying every year from overdoses of prescription opioids; and
WHEREAS, Delaware had the 42nd highest drug overdose mortality rate in the United States in 2014; and
WHEREAS, persons under the age of twenty-five accounted for approximately ten percent of drug overdose deaths in Delaware in 2010; and
WHEREAS, many Delawareans suffer from chronic pain, including individuals with debilitating conditions such as arthritis, fibromyalgia, back pain and life altering injuries; and
WHEREAS, the significant emphasis on limiting substance abuse in Delaware should emphasize every available method to prevent substance abuse notwithstanding the need for appropriate pain treatment utilizing opioid prescription medication; and
WHEREAS, the General Assembly is convinced that it is imperative for people suffering from pain to get the relief they need while minimizing the potential for negative consequences; and
WHEREAS, new technologies are available that can protect the integrity of opioid pain medications by preventing their form from being altered in a manner that would facilitate their illegal use by substance abusers; and
WHEREAS, the introduction of abuse deterrent technologies into the pain medication arena is of significant interest to Delaware as other methods to ensure the continued access of patients to these important medicines and limit the misuse and abuse of those medications and is within the public health and safety interests of Delaware as part of the strategy to limit substance and prescription abuse problems;
NOW, THEREFORE:
BE IT RESOLVED by the House of Representatives of the 148th General Assembly of the State of Delaware, the Senate concurring therein, that the Controller General shall prepare an estimate of costs for inclusion of abuse deterrent formulation technologies for opioids in the State Employee Health Plan and Medicaid formulary coverage in order to assist in the state's continuing efforts to eliminate prescription drug abuse.This information will be submitted to the General Assembly by May 1, 2016.
SYNOPSIS
|
This Concurrent Resolution directs the Controller General to prepare an estimate of costs for inclusion of abuse deterrent formulation technologies for opioids in the State Employee Health Plan and Medicaid formulary coverage in order to assist in the state's continuing efforts to eliminate prescription drug abuse. |
